Loading
Damage to the lungs, heart or liver is a common reason cancer drugs fail. Connected chips of human tissue may spot this earlier than animal tests.
Interstitial lung disease with ADCs, cardiotoxicity with HER2 agents and hepatotoxicity with several classes are poorly predicted by rodents. Coupled microphysiological systems with human lung, heart, liver and kidney compartments and shared circulation can measure organ-specific injury from a candidate at clinically relevant exposures. US legislation now allows non-animal methods to support investigational new drug applications, giving a regulatory route.
Shares Estimation of clinical trial success rates and related parameters, Payload (ADC), Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Drug discovery roadmap: screening in mice → maps of dependency → designing in silico, Lab models that fail to predict what happens in patients.
Shares Interstitial lung disease (ILD) / pneumonitis, Payload (ADC), Toxicity and quality of life are undervalued, Antibody-drug conjugate (ADC).
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.
Shares Estimation of clinical trial success rates and related parameters, Patient-derived organoids, Lab models that fail to predict what happens in patients.